Share

December 2020; 10 (6) ResearchOpen Access

Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS

Andrew Chan, John Rose, Enrique Alvarez, Amit Bar-Or, Helmut Butzkueven, Robert J. Fox, Ralf Gold, Mark Gudesblatt, Jodi Haartsen, Tim Spelman, Katy Wright, Diana Ferraro, Patrizia Sola, Suzanne Hodgkinson, Tomas Kalincik, Jeannette Lechner-Scott, Christopher McGuigan, Karen Spach, Chongshu Chen, Sami Fam, Fan Wu, Catherine Miller
First published January 2, 2020, DOI: https://doi.org/10.1212/CPJ.0000000000000800
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
716

Share

Article Information

vol. 10 no. 6 510-519
DOI: 
https://doi.org/10.1212/CPJ.0000000000000800
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received July 15, 2019
  • Accepted October 22, 2019
  • First Published January 2, 2020.

Article Versions

Copyright & Usage: 
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Andrew Chan, MD, PhD,
    2. John Rose, MD,
    3. Enrique Alvarez, MD, PhD,
    4. Amit Bar-Or, MD,
    5. Helmut Butzkueven, MBBS, PhD,
    6. Robert J. Fox, MD,
    7. Ralf Gold, MD, PhD,
    8. Mark Gudesblatt, MD,
    9. Jodi Haartsen, MS, NP,
    10. Tim Spelman, MBS, BSc,
    11. Katy Wright, MPAS, PA-C,
    12. Diana Ferraro, MD, PhD,
    13. Patrizia Sola, MD, PhD,
    14. Suzanne Hodgkinson, PhD,
    15. Tomas Kalincik, MD, PhD,
    16. Jeannette Lechner-Scott, MD, PhD,
    17. Christopher McGuigan, MD,
    18. Karen Spach, PhD,
    19. Chongshu Chen, PhD,
    20. Sami Fam, PhD,
    21. Fan Wu, PhD and
    22. Catherine Miller, PharmD, MPH
  1. Andrew Chan, MD, PhD,
    2. Scientific Advisory Boards:

    1. (1) Almirall (2) Actelion-Janssen (3) Bayer (4) Biogen (5) Celgene (6) Genzyme (7) Merck (8) Novartis (8) Roche (9) Teva

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Almirall (2) Actelion-Janssen (3) Bayer (4) Biogen (5) Celgene (6) Genzyme (7) Merck (8) Novartis (8) Roche (9) Teva; travel and speaker honoraria, all for University Research funds

    Editorial Boards:

    1. Clinical and Translational Neuroscience (Editorial board) Topic editor, Journal of International medical research

    Patents:

    1. (1) mTOR inhibition as mechanism to increase glucocorticosteroid efficacy

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from Biogen, Genzyme, UCB

    Research Support, Government Entities:

    1. (1) Schweizer Nationalfonds, Principle investigator, 2 years, (2) EU Horizon 2020, Principle Investigator 2 years

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Swiss multiple sclerosis society, Co-PI, 2 years

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. John Rose, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen

    Research Support, Government Entities:

    1. NIH Co-investigator 2018 to 2020 VA 2018-2021

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National Multiple Sclerosis Society, (Co PI) 2016 to 2022; Guthy Jackson Charitable Foundation (Co PI) 2016 to 2020, Friends of MS 2017 to 2020.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Enrique Alvarez, MD, PhD,
    4. Scientific Advisory Boards:

    1. (1) Biogen, (2) Celgene, (3) Genzyme, (4) Genentech, (5) Novartis, (6) TG pharmaceuticals, (7) Actelion, (8) EMD Serono, (9) Bayer

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Rocky Mountain MS Center (2) Biogen, (3) Genentech, and (4) Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Amit Bar-Or, MD,
    5. Scientific Advisory Boards:

    1. Receptos-Celgene, Advisor, Scientific Board, 2011 - Sanofi/Genzyme, Advisor, Scientific board, 2017 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 - Guthy Jackson Greater Good Foundation, Scientific Advisor, 2008- Immune Tolerance Network - Steering Committee, 2016 -

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-Genzyme 2015- GSK, Advisor 2012 - 2014

    Editorial Boards:

    1. (1) Neurology, Editorial Board Member, 2008-2015 (2) Clinical and Experimental Neuroimmunology, Editorial Board Member, 2010 -

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Receptos-Celgene, Advisor, Scientific Board, 2011 - Roche/Genentech, Advisor, Scientific Board, 2008- Novartis, Advisor, Scientific Board, 2012- Sanofi-genzyme - Advisor, 2015 - GSK, Advisor 2012 - 2014 Atara Therapeutics, Advisor, Scientific Board, 2017 -

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Novartis (2) Genzyme-Sanofi (3) Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Helmut Butzkueven, MBBS, PhD,
    6. Scientific Advisory Boards:

    1. Dr Butzkueven served on Scientific Advisory Boards and Study Steering Committees for the MSBase Foundation, Novartis, Biogen, Merck, Roche and Multiple Sclerosis Research Australia

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr Butzkueven's Institution has received support from Novartis, Genzyme, Roche and Biogen (speaker and advisor honoraria) Dr Butzkueven has received support from Merck (travel support and Steering committee honoraria)

    Editorial Boards:

    1. Multiple Sclerosis and Related Disorders, Member, Editorial Board since 2011.

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr Butzkueven has a pro-bono consultancy arrangment for the MS Brain Health Initiative steering committee duties and content creation with Oxford Health Policy Forum Dr Butzkueven's Institution receives income for his consultancy duties for Medday, Roche, Merck, Biogen and Novartis

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr Butzkueven's Institutions have received Research Support from Biogen, Roche and Novartis.

    Research Support, Government Entities:

    1. He is the recipient of a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (1080518), NHMRC Project Grants (1083539)

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr Butzkueven's Institution has received research support from MS Research Australia, the Pennycook Foundation, and Charityworks for MS

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Robert J. Fox, MD,
    7. Scientific Advisory Boards:

    1. Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, and Teva

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board, Neurology Editorial Board, Multiple Sclerosis Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. Multiple Sclerosis and Related Disorders, Demos Medical, 2019

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, and Teva

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. Cleveland Clinic shares rights to intellectual property contained within the MSPT, currently licensed to Qr8 Health and Biogen.

    Research Support, Commercial Entities:

    1. Research grants from Novartis and Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society, RG 4778-A-6, 2013-2019; NIH 1U01NS082329-01A1, 2013-2019; Consortium of MS Centers

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Ralf Gold, MD, PhD,
    8. Scientific Advisory Boards:

    1. (1) TEVA Laquinimod DSMB

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaker honoraria from Biogen, Genzyme, TEVA, Merckserono, BayerSchering,Celgene, Novartis

    Editorial Boards:

    1. SAGE Journal, Aktuelle Neurologie, Experimental Neurology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. From Roche From Merck

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Mark Gudesblatt, MD,
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Acorda (2) Amgen (3) Biogen (4) EMD Serono (5) MEdtronic (6) Novartis (7) Teva

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen (2) EMD Serono (3) Sanofi Genzyme (4) Novartis (5) Genentech (6) Teva

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Jodi Haartsen, MS, NP,
    10. Scientific Advisory Boards:

    1. Biogen Idec Australia Nursing Advisory Board Merck Serono Australia Nursing Advisory Board Roche Australia Nursing Advisory Board

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Speaking and travel Honoraria from Novartis Australia, Roche Australia, Merck Serono Australia, Genzyme and Biogen Australia

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Tim Spelman, MBS, BSc,
    11. Scientific Advisory Boards:

    1. (1) Tysabri Observational Programme Steering Committee - Biogen

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis Australia, travel grant, speaker honoraria; (2) Biogen Idec, travel grant, speaker honoraria

    Editorial Boards:

    1. (1) Journal of the International AIDS Society (JIAS), editorial board member, 2013-present (2) Biomedical Research International, Guest Lead Editor, 2015- present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Katy Wright, MPAS, PA-C,
    12. Scientific Advisory Boards:

    1. 1. Biogen 2. Genzyme 3. Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1. Genzyme 2. Celgene

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Diana Ferraro, MD, PhD,
    13. Scientific Advisory Boards:

    1. Advisory Board for Biogen and Roche

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1)Merck Serono, travel and speaker honoraria 2)TEVA Pharmaceutical Industries, travel and speaker honoraria 3)Novartis, travel and speaker honoraria 4)Biogen Idec, travel and speaker honoraria 5)Sanofi-Genzyme, travel honoraria

    Editorial Boards:

    1. BMC Neurology, Associate Editor since 2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  13. Patrizia Sola, MD, PhD,
    14. Scientific Advisory Boards:

    1. Teva

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1): Merck Serono, travel grants (2): TEVA: travel grants, (3): Biogen Idec: travel grants, (4): Novartis: travel grants (5): Sanofi genzyme Roche

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Suzanne Hodgkinson, PhD,
    15. Scientific Advisory Boards:

    1. Commercial pharma

    Gifts:

    1. Travel assistance

    Funding for travel or speaker honoraria:

    1. Honoraria for speaking

    Editorial Boards:

    1. NONE

    Patents:

    1. The role of cytokine IL-5 in antigen specific T cell tolerance

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NH&MRC project grant 2013-2015

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Tomas Kalincik, MD, PhD,
    16. Scientific Advisory Boards:

    1. (1) Novartis, (2) Merck, (3) Biogen, (4) Roche, (5) Genzyme-Sanofi, (6) Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Novartis, compensation for travel and speaker honoraria (2) Biogen, compensation for travel and speaker honoraria (3) Genzyme-Sanofi, compensation for travel and speaker honoraria (4) Teva, speaker honoraria (5) Merck, compensation for travel and speaker honoraria (6) WebMD Global, speaker honoraria (7) Roche, speaker honoraria (8) BioCSL, speaker honoraria

    Editorial Boards:

    1. (1) Multiple Sclerosis Journal, editorial board member, since 2018 (2) BMC Neurology, associate editor 2017-2018 (3) Frontiers in Neurology, reviewer editor 2017-2018

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) Novartis, (2) Biogen, (3) Genzyme-Sanofi, (4) Teva, (5) Merck, (6) WebMD Global, (7) Roche, (8) BioCSL, (9) Roche

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1) University of Melbourne

    Research Support, Foundations and Societies:

    1. (1) Multiple Sclerosis Research Australia, (2) National Medical and Health Research Committee, (3) Multiple Sclerosis Society, UK, (4) ARSEP, (5) Medical Research Future Fund

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Jeannette Lechner-Scott, MD, PhD,
    17. Scientific Advisory Boards:

    1. I have served in the past on advisory boards for Bayer Health care, Merck Serono, Biogen, Novartis, CSL, Genzyme- Sanofi, Roche and TEVA.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I have accepted travel compensation and honoraria from Biogen, Novartis and Merck Serono.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Scientific project support from (1) Biogen and (2) Novartis and (3) TEVA

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. Hunter Medical Research Institute University of Newcastle Australia

    Research Support, Foundations and Societies:

    1. John Hunter Hospital Charitable Trust

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  17. Christopher McGuigan, MD,
    18. Scientific Advisory Boards:

    1. 1. Commercial: Biogen Roche Novartis Merck Almiral Sanofi Genzyme Sandoz

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Roche Novartis Merck Biogen

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen Roche Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  18. Karen Spach, PhD,
    19. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Employee of and holds stock/stock options in Envision Pharma Group, Fairfield, CT, USA for 4 years; writing was performed as a contract from Biogen Inc.

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)Employee of and holds stock/stock options in Envision Pharma Group, Fairfield, CT, USA for 4 years; writing was performed as a contract from Biogen Inc.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. (1) Employee of and holds stock/stock options in Envision Pharma Group, Fairfield, CT, USA for 4 years; writing was performed as a contract from Biogen Inc.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. (1) Employee of and holds stock/stock options in Envision Pharma Group, Fairfield, CT, USA for 4 years; writing was performed as a contract from Biogen Inc.

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  19. Chongshu Chen, PhD,
    20. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Biogen, Senior Biostatistician, 2 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Biogen, 2 years

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  20. Sami Fam, PhD,
    21. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Agios Pharmaceuticals, Medical Director, March 2019- present Biogen, Associate Medical Director, May 2013-March 2019

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  21. Fan Wu, PhD and
    22. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Biogen

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. (1) Biogen Stock/Stock Options, Medical Equipment & Materials: (1) Biogen

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  22. Catherine Miller, PharmD, MPH
    23. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Biogen, Global Medical Director, 4 years

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. Biogen, 3.5 years

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology (AC), Inselspital, Bern University Hospital, University of Bern, Switzerland; Division of Neuroimmunology and Neurovirology (JR), University of Utah, Salt Lake City, UT; Brain Institute (JR), University of Utah, Salt Lake City, UT; Department of Neurology (JR), University of Utah, Salt Lake City, UT; Rocky Mountain Multiple Sclerosis Center at the University of Colorado (EA), Aurora, CO; Department of Neurology and Center for Neuroinflammation and Experimental Therapeutics (AB-O), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Children's Hospital of Philadelphia (AB-O), Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; Central Clinical School (HB), Monash University, VIC, Australia; Mellen Center for Multiple Sclerosis Treatment and Research (RJF), Cleveland Clinic, OH; Department of Neurology (RG), St. Josef-Hospital, Ruhr University Bochum, Germany; South Shore Neurologic Association PC (MG), Patchogue, NY; Eastern Health MS Service (JH), Box Hill, VIC, Australia; Department of Medicine and Melbourne Brain Centre at the Royal Melbourne Hospital (TS), University of Melbourne, Parkville, VIC, Australia; Department of Neurology and Neurotherapeutics (KW), University of Texas Southwestern Medical Center, Multiple Sclerosis and Neuroimmunology Imaging Program, Clinical Center for Multiple Sclerosis, Dallas, TX; Department of Neuroscience (DF, PS), Neurology Unit, Azienda Ospedaliera Universitaria, Modena, Italy; Liverpool Hospital (SH), NSW, Australia; Department of Medicine (TK), CORe Unit, University of Melbourne, VIC, Australia; Department of Neurology (TK), Royal Melbourne Hospital, VIC, Australia; School of Medicine and Public Health (JL-S), University Newcastle, NSW, Australia; Department of Neurology (JL-S), John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia; Department of Neurology (C. McGuigan), St. Vincent's University Hospital and University College, Dublin, Ireland; Envision Pharma Group (KS), Fairfield, CT; and Biogen (CC, SF, FW, C. Miller), Cambridge, MA.
  1. Correspondence
    Catherine Miller catherine.miller{at}biogen.com
View Full Text

Article usage

Article usage: January 2020 to January 2021

AbstractFullPdfSource
Jan 2020244095Highwire
Feb 2020167080Highwire
Mar 202096054Highwire
Apr 202051044Highwire
May 202057038Highwire
Jun 202053023Highwire
Jul 202065042Highwire
Aug 202033033Highwire
Sep 202045048Highwire
Oct 202042043Highwire
Nov 202055047Highwire
Dec 202026771108Highwire
Jan 20211345861Highwire

Cited By...

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.cp.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on The Nerve!

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate The Nerve! Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me